About InpharmD
InpharmD is a company based in Atlanta (United States) founded in 2014. InpharmD has raised $6.63 million across 2 funding rounds from investors including 645 Ventures, Atlanta Ventures and Y Combinator. InpharmD operates in a competitive market with competitors including Fullscript, Omega Therapeutics, PharMerica, BiomeSense and BAMF Health, among others.
- Headquarter Atlanta, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$6.63 M (USD)
in 2 rounds
-
Latest Funding Round
$6.5 M (USD), Seed
Dec 07, 2023
-
Investors
645 Ventures
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of InpharmD
Unlock access to complete
Unlock access to complete
Funding Insights of InpharmD
InpharmD has successfully raised a total of $6.63M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $6.5 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in InpharmD
InpharmD has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include 645 Ventures, Atlanta Ventures and Y Combinator.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
US focused seed and early-stage VC firm
|
Locked | Locked | Locked | |
|
Venture capital fund and accelerator focused on startups
|
Locked | Locked | Locked | |
|
Early-stage startups are accelerated via funding and educational programs.
|
Locked | Locked | Locked |
Investor details for InpharmD
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by InpharmD
Investment portfolio details for InpharmD
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - InpharmD
Detailed financials for InpharmD
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Inpharmd Comparisons
Peer comparison for InpharmD
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of InpharmD
InpharmD operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Fullscript, Omega Therapeutics, PharMerica, BiomeSense and BAMF Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Supplements dispensing platform is provided for health practitioners.
|
|
| Locked | Locked | Locked |
Platform for human genome study is provided for precision medicine.
|
|
| Locked | Locked | Locked |
Pharmacy needs of nursing facilities and dispensing software are served.
|
|
| Locked | Locked | Locked |
AI-enabled platform for microbiome data generation and analysis is developed.
|
|
| Locked | Locked | Locked |
AI-enabled molecular imaging and theranostics for disease diagnostics are developed.
|
Detailed competitors of InpharmD
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Inpharmd
Complete news archive for InpharmD
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about InpharmD
InpharmD was founded in 2014 and raised its 1st funding round 7 years after it was founded.
InpharmD is headquartered in Atlanta, United States. It is registered at Atlanta, Georgia, United States.
InpharmD is a funded company, having raised a total of $6.63M across 2 funding rounds to date.
InpharmD was founded in 2014 in Atlanta, United States, within the healthcare technology sector. A digital platform is operated for providers decision support, where medication-related questions are submitted via website or app. Customized, evidence-based responses are generated from an integrated database, including literature summaries, within specified timeframes. Drug information inquiries are addressed through concise evidence overviews to aid clinical decisions.
InpharmD's top competitors include Omega Therapeutics, CueZen and Fullscript.
InpharmD has 5 investors. Key investors include 645 Ventures, Atlanta Ventures, Y Combinator, Qlarant, and ELC.